Ranbaxy Buys Biovel For An Entry Into Vaccines and Biotherapeutics
This article was originally published in PharmAsia News
Executive Summary
MUMBAI - Lucrative opportunities in the business of vaccines has attracted one more big drug maker. India's Ranbaxy clinched a deal with Bangalore-based Biovel in an asset buyout that is expected to help it gain foothold in a market that reached $700 million in India and $21 billion in worldwide sales in 2008